Affinity Biomarker Labs, based in London, UK, is the latest partner to join the NADMED network, offering NAD+ and NADH testing upon request. Established in 2017 at Imperial College London’s White City Campus, Affinity Biomarker Labs was founded by a team of clinical...
Research and Markets, one of the world’s leading market research firms, has identified NADMED as one of the fastest-growing clinical laboratory tests in Europe over the next five years. The molecular diagnostics segment, a key area of focus, is projected to achieve a...
The investment round was led by Finnish science-based startup investor Nordic Science Investments (NSI). Additional funding was secured from previous investors Voima Ventures and University of Helsinki Funds, from a number of private European investors, and a grant...
A study involving a healthy population of 1162 individuals revealed that persistent high niacin intake, whether through fortified foods or supplements, raises the risk of cardiovascular disease by elevating the metabolite 4PY. The study further suggests that similar...
In a recent study, researchers found that high NAD(H)+ amounts slow down the growth of highly proliferative cancer cells by slowing down their DNA replication. The authors suggest that high NAD(H)+ in combination with cancer drug 5-fluorouridine could selectively kill...
